FDA action has harmed business, says Utah
This article was originally published in Clinica
Executive Summary
Utah Medical is feeling the impact of the recent blow dealt by the US FDA when the agency announced its intention to seek a permanent injunction against the company from selling medical devices. The decision, considered to be a particularly aggressive move by the FDA, was the latest twist in the ongoing dispute between the agency and Utah, in which the FDA claims that the company's production facility does not conform to certain federal manufacturing standards (see Clinica No 1120, p 11).
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.